Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide

摘要

We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

主权项

1. A method of treatment comprising administering a therapeutically effective amount of an antibody selected from the group consisting of:
(a) an antibody which binds to PRL-1 comprising a heavy chain variable region sequence comprising SEQ ID NO: 2 and a light chain variable region sequence comprising SEQ ID NO: 4 (b) an antigen binding fragment of (a);or a pharmaceutical composition comprising such an antibody to an individual suffering from a PRL-1-expressing cancer.